Association of radiomic features with epidermal growth factor receptor mutation status in non-small cell lung cancer and survival treated with tyrosine kinase inhibitors

Since the discovery of the fact that tyrosine kinase inhibitors could improve progression-free survival for patients with advanced non-small cell lung cancer compared with traditional chemotherapy, it has been extremely important to identify epidermal growth factor receptor mutation status in treatment stratification. Although lack of sufficient biopsy samples limit the precise detection of epidermal growth factor receptor mutation status in clinical practice, and it is difficult to identify the sensitive patients who confer favorable response to tyrosine kinase inhibitors. An increasing number of scholars tried to deal with these problems using methods based on the non-invasive imaging including computed tomography and PET to find the association with epidermal growth factor receptor mutation status and survival treated with tyrosine kinase inhibitor in non-small cell lung cancer. Although the conclusions have not reached a consensus, quantitative and high-throughput radiomics have brought us a new direction and might successfully help identify patients undergoing tyrosine kinase inhibitors who could get significant benefits.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Review Article Source Type: research

Related Links:

AbstractBackgroundAcute exacerbation (AE) of interstitial lung disease (ILD) is a fatal adverse event in the treatment of lung cancer patients with ILD. The value of pre-treatment radiological findings obtained by high-resolution computed tomography for the detection of anticancer treatment-related AE of ILD has not been established.MethodsTwo medical record-based retrospective studies were performed. The chemotherapy cohort included 105 lung cancer patients with ILD who received chemotherapy at Tokyo Medical and Dental University between October 2008 and December 2017. The immune checkpoint inhibitor (ICI) cohort included...
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Maximum diameter of lesions ≤3cm, early clinical stage, solitary lesion in the lung and RFA combined with cisplatin and carboplatin chemotherapy and/or tyrosine kinase inhibitors (TKI) all were positive factors of local efficacy and survival after RFA of primary NSCLC. PMID: 31646816 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
AbstractPurposePrevious literature has reported contradicting results regarding the relationship between tumor volume changes during radiotherapy treatment for non-small cell lung cancer (NSCLC) patients and locoregional recurrence-free rate or overall survival. The aim of this study is to validate the results from a  previous study by using a different volume extraction procedure and evaluating an external validation dataset.MethodsFor two datasets of 94 and 141 NSCLC patients, gross tumor volumes were determined manually to investigate the relationship between tumor volume regression and locoregional control us...
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
In a patient who had been diagnosed of located squamous cell lung carcinoma, pneumonectomy and adjuvant chemotherapy were performed. Brain recurrence and subsequent lung metastatic disease were uncontrolled by neurosurgery, holocranial radiotherapy and first-line chemotherapy. In August 2015, appearance of leptomeningeal carcinomatosis triggered severe clinical deterioration and threatened the patient's life. Anti-PD1 immune checkpoint inhibitor Nivolumab was initiated in an attempt to stop tumour growth, achieving a spectacular brain and pulmonary complete response and clinical improvement, without serious adverse effects...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS ADC changing rate between first and second cycles of chemotherapy could sensitively distinguish chemo-sensitive and chemo-resistant tumors at earlier stages, which may direct treatment adjustment and improve the prognosis of patients. PMID: 31476196 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
The treatment of stage III NSCLC involves a multi-disciplinary approach and careful patient selection to determine which resectable patients might benefit from a trimodality treatment [1,2]. Neoadjuvant chemotherapy administered prior to surgery can reduce tumor extent and metastases, thereby improving resectability. The role of surgery in stage IIIA patients still remains controversial. Survival benefit of surgery in this setting has long been debated and has proven difficult to demonstrate in multi-institute trials compared to definitive chemoradiation [1,3].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Abstract In order to optimize patient-tailored chemotherapy, a non-small-cell lung cancer (NSCLC)-liver metastasis patient-derived tumor xenograft (PDTX) model is developed. Computed tomography (CT)-guided NSCLC percutaneous biopsy was subcutaneously inoculated into the flank of non-obese diabetic/severe combined immunodeficiency (NOD/SCID) female mice (PDTX F1) and allowed to reach 500 mm3 volume. Then, the tumors were re-transplanted into Balb/c nude mice and liver metastasis was confirmed (PDTX F2), which were further assigned into doxorubicin (DOX), docetaxel (DTX), and nontreatment control group. H&E staining...
Source: Bioscience Reports - Category: Biomedical Science Authors: Tags: Biosci Rep Source Type: research
This case report qualified for local institutional review board waiver of review. Bronchopleural fistula (BPF) is a known but rare complication of thermal ablation of the lungs, and, currently, literature on causative factors and treatment is limited to case reports. A 40-year-old man with metastatic non-small cell lung cancer (mixed neuroendocrine and adenomatous features) had a solitary 3.0-cm right upper lobe lung mass (Fig 1a) that was growing despite chemotherapy and radiation. Microwave ablation was performed under general anesthesia and computed tomography (CT) fluoroscopy guidance using a single 13-gauge antenna (E...
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: Tags: Letter to the Editor Source Type: research
In a study led by UCLA investigators, treatment with the immunotherapy drug pembrolizumab helped more than 15% of people with advanced non-small cell lung cancer live for at least five years — and 25% of patients whose tumor cells had a specific protein lived at least that long.When the study began in 2012, the average five-year survival rate was just 5.5%  for people with that type of cancer.The study, conducted by researchers at theUCLA Jonsson Comprehensive Cancer Center and more than 30 other centers, was the first to evaluate pembrolizumab as a treatment for lung cancer. The results were featured in aJune 1...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
CONCLUSIONS: Several potential prognostic biomarkers of PET/CT imaging have been extracted for predicting survival and selecting patients with NSCLC who are more likely to benefit from chemotherapy. The identification may accelerate the development of AI methods to improve treatment outcome for NSCLC. PMID: 31144578 [PubMed - in process]
Source: Molecular Imaging - Category: Radiology Tags: Mol Imaging Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | CT Scan | Lung Cancer | Non-Small Cell Lung Cancer | Nuclear Medicine